"Molecule ChEMBL ID";"Molecule Name";"Molecule Max Phase";"Molecular Weight";"#RO5 Violations";"AlogP";"Compound Key";"Smiles";"Standard Type";"Standard Relation";"Standard Value";"Standard Units";"pChEMBL Value";"Data Validity Comment";"Comment";"Uo Units";"Ligand Efficiency BEI";"Ligand Efficiency LE";"Ligand Efficiency LLE";"Ligand Efficiency SEI";"Potential Duplicate";"Assay ChEMBL ID";"Assay Description";"Assay Type";"BAO Format ID";"BAO Label";"Assay Organism";"Assay Tissue ChEMBL ID";"Assay Tissue Name";"Assay Cell Type";"Assay Subcellular Fraction";"Assay Parameters";"Assay Variant Accession";"Assay Variant Mutation";"Target ChEMBL ID";"Target Name";"Target Organism";"Target Type";"Document ChEMBL ID";"Source ID";"Source Description";"Document Journal";"Document Year";"Cell ChEMBL ID";"Properties";"Action Type";"Standard Text Value";"Value"
"CHEMBL5605274";"";"None";"390.39";"0";"4.36";"ASAP-0031221";"O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]c(-c3ccccc3F)nc12";"IC50";"'='";"3856.0";"nM";"5.41";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.542 None | IC50 CI (lower) = 3.197 uM | IC50 CI (upper) = 4.651 uM | Maximum measured = 93.83 None | Maximum response = 100.0 % | Minimum measured = -3.458 None | R squared = 0.968 None";"";"";"3.856"
"CHEMBL5605366";"";"None";"425.92";"0";"3.27";"ASAP-0029888";"O=C(NC1CCOCC1)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.002 None | Maximum measured = 43.14 None | Maximum response = 100.0 % | Minimum measured = -3.642 None | R squared = 0.957 None";"";"";"99.5"
"CHEMBL5605468";"";"None";"295.32";"0";"3.16";"ASAP-0029832";"O=C(Nc1ccc2c(c1)CNC2)c1cc(F)c2[nH]ccc2c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 11.46 None | Maximum measured = 17.97 None | Maximum response = 100.0 % | Minimum measured = -4.932 None | R squared = 0.717 None";"";"";"99.5"
"CHEMBL5604849";"";"None";"409.96";"0";"4.89";"ASAP-0030790";"O=C(NCCC1CC1)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = 0.543 None | Minimum measured = -36.85 None";"";"";"99.5"
"CHEMBL5604326";"";"None";"333.39";"0";"3.15";"ASAP-0030062";"C=CC[C@H]1NCc2cc(NC(=O)c3cccc4c3CC(=O)N4)ccc21";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.95 None | Maximum measured = 4.988 None | Maximum response = 100.0 % | Minimum measured = -2.535 None | R squared = 0.302 None";"";"";"99.5"
"CHEMBL5605255";"";"None";"423.95";"0";"4.61";"ASAP-0030850";"C=CC[C@H]1NCc2cc(N[C@H](C(=O)NC(C)C)c3cc(Cl)cc4[nH]ncc34)ccc21";"IC50";"'='";"81831.0";"nM";"4.09";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 0.858 None | IC50 CI (lower) = 74.99 uM | IC50 CI (upper) = 89.3 uM | Maximum measured = 51.98 None | Maximum response = 100.0 % | Minimum measured = -0.731 None | R squared = 0.991 None";"";"";"81.831"
"CHEMBL5606236";"";"None";"375.20";"0";"3.32";"ASAP-0030085";"O=C(Nc1cc2c(cc1Br)CNC2)c1cc(F)cc2[nH]ncc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 0.955 None | Maximum measured = 25.93 None | Maximum response = 100.0 % | Minimum measured = -5.756 None | R squared = 0.885 None";"";"";"99.5"
"CHEMBL5605069";"";"None";"311.77";"0";"3.68";"ASAP-0030001";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2cc[nH]c12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = -0.596 None | Minimum measured = -43.7 None";"";"";"99.5"
"CHEMBL5606033";"";"None";"293.33";"0";"2.04";"ASAP-0029950";"O=C1Cc2cc(C(=O)Nc3ccc4c(c3)CNC4)ccc2N1";"IC50";"'='";"4473.0";"nM";"5.35";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.028 None | IC50 CI (lower) = 4.002 uM | IC50 CI (upper) = 4.999 uM | Maximum measured = 100.25 None | Maximum response = 100.0 % | Minimum measured = -1.387 None | R squared = 0.99 None";"";"";"4.473"
"CHEMBL5606429";"";"None";"378.41";"0";"3.36";"ASAP-0031147";"O=C(Nc1cc2c(c(C3=CCOCC3)c1)CNC2)c1cc(F)cc2[nH]ncc12";"IC50";"'='";"39867.0";"nM";"4.40";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.145 None | IC50 CI (lower) = 36.06 uM | IC50 CI (upper) = 44.07 uM | Maximum measured = 92.61 None | Maximum response = 100.0 % | Minimum measured = -5.77 None | R squared = 0.975 None";"";"";"39.867"
"CHEMBL5604988";"";"None";"399.52";"0";"4.88";"ASAP-0031461";"NCc1cccc(-c2csc3cc(C(=O)Nc4ccc5c(c4)CNC5)ccc23)c1";"IC50";"'='";"29855.0";"nM";"4.53";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.726 None | IC50 CI (lower) = 27.62 uM | IC50 CI (upper) = 32.28 uM | Maximum measured = 94.59 None | Maximum response = 100.0 % | Minimum measured = -2.095 None | R squared = 0.988 None";"";"";"29.855"
"CHEMBL5598749";"";"None";"421.88";"0";"4.94";"ASAP-0020915";"O=C(Nc1cc(Cl)cc(C(=O)Nc2ccc3c(c2)CNC3)c1)OCc1ccccc1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.255 None | Maximum measured = 26.84 None | Maximum response = 100.0 % | Minimum measured = -11.71 None | R squared = 0.606 None";"";"";"99.5"
"CHEMBL5605691";"";"None";"312.42";"0";"2.75";"ASAP-0027597";"Cc1c(C(=O)Nc2cc(CCCN)ccn2)cc(C2CC2)n1C";"IC50";"'='";"25482.0";"nM";"4.59";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.774 None | IC50 CI (lower) = 23.97 uM | IC50 CI (upper) = 27.09 uM | Maximum measured = 97.02 None | Maximum response = 100.0 % | Minimum measured = -2.838 None | R squared = 0.991 None";"";"";"25.482"
"CHEMBL5605142";"";"None";"474.95";"1";"6.00";"ASAP-0028884";"C=CC[C@H](Nc1cc(Cl)cc(NC(=O)OCc2ccccc2)c1)c1cccc(-c2nn[nH]n2)c1";"IC50";"'='";"6406.0";"nM";"5.19";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.23 None | IC50 CI (lower) = 5.656 uM | IC50 CI (upper) = 7.256 uM | Maximum measured = 100.48 None | Maximum response = 100.0 % | Minimum measured = -5.461 None | R squared = 0.986 None";"";"";"6.406"
"CHEMBL5605540";"";"None";"452.94";"0";"4.45";"ASAP-0027609";"CNC(=O)[C@H](Nc1cccc(CN)c1)c1cc(Cl)cc(NC(=O)OCc2ccccc2)c1";"IC50";"";"";"";"";"";"";"";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = 18.22 None | Minimum measured = -12.27 None";"";"IC50 could not be calculated";""
"CHEMBL5604249";"";"None";"406.91";"1";"5.82";"ASAP-0022797";"NCc1cccc([C@H]2C[C@@H]2c2cc(Cl)cc(NC(=O)OCc3ccccc3)c2)c1";"IC50";"'='";"25334.0";"nM";"4.60";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.833 None | IC50 CI (lower) = 19.56 uM | IC50 CI (upper) = 32.81 uM | Maximum measured = 85.65 None | Maximum response = 100.0 % | Minimum measured = -19.56 None | R squared = 0.903 None";"";"";"25.334"
"CHEMBL5606319";"";"None";"426.47";"0";"2.76";"ASAP-0031155";"O=C(Nc1cc2c(c(C3=CCS(=O)(=O)CC3)c1)CNC2)c1cc(F)cc2[nH]ncc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.197 None | Maximum measured = 46.87 None | Maximum response = 100.0 % | Minimum measured = -5.698 None | R squared = 0.923 None";"";"";"99.5"
"CHEMBL5605985";"";"None";"416.48";"0";"2.84";"ASAP-0031120";"CC(C)(c1nc2c(C(=O)Nc3ccc4c(c3)CNC4)cc(F)cc2[nH]1)S(C)(=O)=O";"IC50";"'='";"16069.0";"nM";"4.79";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.922 None | IC50 CI (lower) = 14.49 uM | IC50 CI (upper) = 17.82 uM | Maximum measured = 93.58 None | Maximum response = 100.0 % | Minimum measured = -6.653 None | R squared = 0.979 None";"";"";"16.069"
"CHEMBL5606112";"";"None";"337.45";"0";"3.26";"ASAP-0031277";"NCCc1csc2cc(C(=O)Nc3ccc4c(c3)CNC4)ccc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.785 None | Maximum measured = 27.18 None | Maximum response = 100.0 % | Minimum measured = -4.449 None | R squared = 0.755 None";"";"";"99.5"
"CHEMBL5604539";"";"None";"388.39";"0";"3.44";"ASAP-0030867";"O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]ccc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = -2.086 None | Minimum measured = -17.29 None";"";"";"99.5"
"CHEMBL5606201";"";"None";"389.85";"0";"3.93";"ASAP-0030082";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2nn(-c3ccccc3)nc12";"IC50";"'='";"2690.0";"nM";"5.57";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 20.62 None | IC50 CI (lower) = 0.0 uM | IC50 CI (upper) = 4763903498158866000 uM | Maximum measured = 97.29 None | Maximum response = 100.0 % | Minimum measured = -12.26 None | R squared = 0.965 None";"";"";"2.69"
"CHEMBL5605533";"";"None";"418.88";"0";"4.75";"ASAP-0029841";"Cc1cccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(Cl)cc3[nH]2)c1O";"IC50";"'='";"4255.0";"nM";"5.37";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 4.058 None | IC50 CI (lower) = 3.316 uM | IC50 CI (upper) = 5.459 uM | Maximum measured = 97.45 None | Maximum response = 100.0 % | Minimum measured = -17.93 None | R squared = 0.972 None";"";"";"4.255"
"CHEMBL5599838";"";"None";"459.98";"1";"5.16";"ASAP-0030826";"CC(C)NC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]c(-c3ccccc3)nc12";"IC50";"'='";"7461.0";"nM";"5.13";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 0.982 None | IC50 CI (lower) = 6.899 uM | IC50 CI (upper) = 8.069 uM | Maximum measured = 94.12 None | Maximum response = 100.0 % | Minimum measured = -2.791 None | R squared = 0.995 None";"";"";"7.461"
"CHEMBL5598576";"";"None";"405.88";"0";"4.36";"ASAP-0029491";"O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.645 None | Maximum measured = 43.75 None | Maximum response = 100.0 % | Minimum measured = -3.988 None | R squared = 0.964 None";"";"";"99.5"
"CHEMBL5604344";"";"None";"373.21";"0";"2.47";"ASAP-0029916";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Br)cc2[nH]c(=O)[nH]c12";"IC50";"'='";"32728.0";"nM";"4.49";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.06 None | IC50 CI (lower) = 29.68 uM | IC50 CI (upper) = 36.09 uM | Maximum measured = 82.27 None | Maximum response = 100.0 % | Minimum measured = -3.972 None | R squared = 0.977 None";"";"";"32.728"
"CHEMBL5604418";"";"None";"351.88";"0";"4.95";"ASAP-0029785";"Clc1cc([C@@H]2C[C@H]2c2cccc(C3CCNCC3)c2)c2cn[nH]c2c1";"IC50";"'='";"5945.0";"nM";"5.23";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 13.62 None | IC50 CI (lower) = 0.0 uM | IC50 CI (upper) = 494447660689838100 uM | Maximum measured = 100.38 None | Maximum response = 100.0 % | Minimum measured = -12.78 None | R squared = 0.989 None";"";"";"5.945"
"CHEMBL5598927";"";"None";"372.22";"0";"2.80";"ASAP-0029728";"O=C1Cc2c(cc(Br)cc2C(=O)Nc2ccc3c(c2)CNC3)N1";"IC50";"'='";"84550.0";"nM";"4.07";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.888 None | IC50 CI (lower) = 78.56 uM | IC50 CI (upper) = 91.0 uM | Maximum measured = 58.65 None | Maximum response = 100.0 % | Minimum measured = -3.028 None | R squared = 0.976 None";"";"";"84.55"
"CHEMBL5598845";"";"None";"356.22";"0";"3.79";"ASAP-0029002";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Br)cc2[nH]ccc12";"IC50";"'='";"34724.0";"nM";"4.46";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.877 None | IC50 CI (lower) = 32.99 uM | IC50 CI (upper) = 36.55 uM | Maximum measured = 88.92 None | Maximum response = 100.0 % | Minimum measured = -0.67 None | R squared = 0.992 None";"";"";"34.724"
"CHEMBL5605162";"";"None";"387.87";"0";"3.27";"ASAP-0028981";"CNC(=O)[C@H](Nc1cc(CN)cc(C(=O)O)c1)c1cc(Cl)cc(C2CC2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.599 None | Maximum measured = 5.598 None | Maximum response = 100.0 % | Minimum measured = -2.665 None | R squared = 0.449 None";"";"";"99.5"
"CHEMBL5598591";"";"None";"373.29";"0";"4.60";"ASAP-0029041";"CC(C)(C)c1cc(Br)cc(C(=O)Nc2ccc3c(c2)CNC3)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = -0.891 None | Minimum measured = -23.32 None";"";"";"99.5"
"CHEMBL5598577";"";"None";"326.79";"0";"3.11";"ASAP-0029079";"O=C(Nc1ccc2c(c1)CNCC2)c1cc(Cl)cc2[nH]ncc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.276 None | Maximum measured = 33.58 None | Maximum response = 100.0 % | Minimum measured = -2.39 None | R squared = 0.972 None";"";"";"99.5"
"CHEMBL5598593";"";"None";"309.76";"0";"3.59";"ASAP-0027972";"Clc1ccc2[nH]cc(Cc3ccc(-c4nn[nH]n4)cc3)c2c1";"IC50";"'='";"62907.0";"nM";"4.20";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.384 None | IC50 CI (lower) = 60.52 uM | IC50 CI (upper) = 65.38 uM | Maximum measured = 83.79 None | Maximum response = 100.0 % | Minimum measured = -1.661 None | R squared = 0.992 None";"";"";"62.907"
"CHEMBL5605497";"";"None";"463.97";"1";"5.94";"ASAP-0023377";"N[C@H]1CC[C@H](c2ccc(NC(=O)c3cc(Cl)cc(NC(=O)OCc4ccccc4)c3)cc2)C1";"IC50";"'='";"8493.0";"nM";"5.07";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.316 None | IC50 CI (lower) = 7.484 uM | IC50 CI (upper) = 9.637 uM | Maximum measured = 100.01 None | Maximum response = 100.0 % | Minimum measured = -11.23 None | R squared = 0.97 None";"";"";"8.493"
"CHEMBL3740727";"";"None";"719.79";"2";"2.06";"ASAP-0000570";"N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1";"IC50";"'='";"1033.0";"nM";"5.99";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.062 None | IC50 CI (lower) = 0.989 uM | IC50 CI (upper) = 1.079 uM | Maximum measured = 99.36 None | Maximum response = 100.0 % | Minimum measured = 4.771 None | R squared = 0.998 None";"";"";"1.033"
"CHEMBL3919119";"";"None";"454.34";"None";"None";"ASAP-0015081";"N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(CN)cc1)NC(=O)c1ccccc1)B(O)O";"IC50";"'='";"315.0";"nM";"6.50";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.113 None | IC50 CI (lower) = 0.297 uM | IC50 CI (upper) = 0.334 uM | Maximum measured = 99.79 None | Maximum response = 100.0 % | Minimum measured = 12.94 None | R squared = 0.996 None";"";"";"0.315"
"CHEMBL5605856";"";"None";"406.91";"1";"5.82";"ASAP-0027760";"NCc1ccc([C@H]2C[C@@H]2c2cc(Cl)cc(NC(=O)OCc3ccccc3)c2)cc1";"IC50";"'='";"8889.0";"nM";"5.05";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 5.4 None | IC50 CI (lower) = 8.34 uM | IC50 CI (upper) = 9.474 uM | Maximum measured = 97.61 None | Maximum response = 100.0 % | Minimum measured = -10.59 None | R squared = 0.987 None";"";"";"8.889"
"CHEMBL5605947";"";"None";"435.91";"0";"4.99";"ASAP-0027652";"O=C(Nc1cc(Cl)cc(C(=O)Nc2ccc3c(c2)CCNC3)c1)OCc1ccccc1";"IC50";"'='";"47725.0";"nM";"4.32";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.674 None | IC50 CI (lower) = 42.79 uM | IC50 CI (upper) = 53.23 uM | Maximum measured = 87.09 None | Maximum response = 100.0 % | Minimum measured = -12.68 None | R squared = 0.945 None";"";"";"47.725"
"CHEMBL5598679";"";"None";"293.33";"0";"2.04";"ASAP-0029208";"O=C1Cc2c(cccc2C(=O)Nc2ccc3c(c2)CNC3)N1";"IC50";"'='";"11306.0";"nM";"4.95";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.732 None | IC50 CI (lower) = 10.58 uM | IC50 CI (upper) = 12.08 uM | Maximum measured = 99.43 None | Maximum response = 100.0 % | Minimum measured = -2.578 None | R squared = 0.991 None";"";"";"11.306"
"CHEMBL5598615";"";"None";"367.25";"0";"4.46";"ASAP-0029045";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Br)cc2ccccc12";"IC50";"'='";"83668.0";"nM";"4.08";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.388 None | IC50 CI (lower) = 76.73 uM | IC50 CI (upper) = 91.23 uM | Maximum measured = 63.44 None | Maximum response = 100.0 % | Minimum measured = -9.201 None | R squared = 0.932 None";"";"";"83.668"
"CHEMBL5605520";"";"None";"352.82";"0";"2.97";"ASAP-0028990";"OCC#C[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12";"IC50";"'='";"19396.0";"nM";"4.71";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.531 None | IC50 CI (lower) = 17.8 uM | IC50 CI (upper) = 21.14 uM | Maximum measured = 96.3 None | Maximum response = 100.0 % | Minimum measured = -11.79 None | R squared = 0.984 None";"";"";"19.396"
"CHEMBL5604375";"";"None";"323.79";"0";"3.50";"ASAP-0028904";"N#C[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = 3.796 None | Minimum measured = -7.933 None";"";"";"99.5"
"CHEMBL3919119";"";"None";"454.34";"None";"None";"ASAP-0015081";"N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(CN)cc1)NC(=O)c1ccccc1)B(O)O";"IC50";"'='";"310.0";"nM";"6.51";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.212 None | IC50 CI (lower) = 0.299 uM | IC50 CI (upper) = 0.322 uM | Maximum measured = 99.81 None | Maximum response = 100.0 % | Minimum measured = 12.63 None | R squared = 0.998 None";"";"";"0.31"
"CHEMBL5605561";"";"None";"333.40";"0";"2.11";"ASAP-0031692";"O=C(Nc1ccc2c(c1)CNC2)c1cccc2c(C3CNC3)n[nH]c12";"IC50";"'='";"92913.0";"nM";"4.03";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.221 None | IC50 CI (lower) = 79.45 uM | IC50 CI (upper) = 108.65 uM | Maximum measured = 50.77 None | Maximum response = 100.0 % | Minimum measured = -4.58 None | R squared = 0.954 None";"";"";"92.913"
"CHEMBL5605664";"";"None";"390.39";"0";"4.36";"ASAP-0031237";"O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]c(-c3ccc(F)cc3)nc12";"IC50";"'='";"2796.0";"nM";"5.55";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.2 None | IC50 CI (lower) = 2.27 uM | IC50 CI (upper) = 3.445 uM | Maximum measured = 94.29 None | Maximum response = 100.0 % | Minimum measured = -2.07 None | R squared = 0.95 None";"";"";"2.796"
"CHEMBL5605372";"";"None";"323.42";"0";"3.22";"ASAP-0031633";"NCc1csc2cc(C(=O)Nc3ccc4c(c3)CNC4)ccc12";"IC50";"'='";"9985.0";"nM";"5.00";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.804 None | IC50 CI (lower) = 9.104 uM | IC50 CI (upper) = 10.95 uM | Maximum measured = 99.12 None | Maximum response = 100.0 % | Minimum measured = -7.829 None | R squared = 0.985 None";"";"";"9.985"
"CHEMBL5605310";"";"None";"399.52";"0";"4.88";"ASAP-0031492";"NCc1ccc(-c2csc3cc(C(=O)Nc4ccc5c(c4)CNC5)ccc23)cc1";"IC50";"'='";"31660.0";"nM";"4.50";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.567 None | IC50 CI (lower) = 28.38 uM | IC50 CI (upper) = 35.32 uM | Maximum measured = 65.86 None | Maximum response = 100.0 % | Minimum measured = -6.825 None | R squared = 0.97 None";"";"";"31.66"
"CHEMBL5604216";"";"None";"397.41";"0";"4.10";"ASAP-0031247";"N#Cc1cccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)c1";"IC50";"'='";"2412.0";"nM";"5.62";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.874 None | IC50 CI (lower) = 2.032 uM | IC50 CI (upper) = 2.863 uM | Maximum measured = 92.71 None | Maximum response = 100.0 % | Minimum measured = -3.853 None | R squared = 0.967 None";"";"";"2.412"
"CHEMBL5605238";"";"None";"375.50";"0";"4.13";"ASAP-0031464";"O=C(Nc1ccc2c(c1)CNC2)c1ccc2c(C3=CCNCC3)csc2c1";"IC50";"'='";"56250.0";"nM";"4.25";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.04 None | IC50 CI (lower) = 52.7 uM | IC50 CI (upper) = 60.04 uM | Maximum measured = 77.81 None | Maximum response = 100.0 % | Minimum measured = -3.359 None | R squared = 0.985 None";"";"";"56.25"
"CHEMBL3740727";"";"None";"719.79";"2";"2.06";"ASAP-0000570";"N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1";"IC50";"'='";"926.0";"nM";"6.03";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.114 None | IC50 CI (lower) = 0.896 uM | IC50 CI (upper) = 0.957 uM | Maximum measured = 99.76 None | Maximum response = 100.0 % | Minimum measured = 2.677 None | R squared = 0.999 None";"";"";"0.926"
"CHEMBL5598732";"";"None";"359.27";"0";"4.43";"ASAP-0029050";"CC(C)c1cc(Br)cc(C(=O)Nc2ccc3c(c2)CNC3)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = -0.663 None | Minimum measured = -23.93 None";"";"";"99.5"
"CHEMBL5598631";"";"None";"312.80";"0";"3.68";"ASAP-0029051";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2c1CCC2";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = -0.342 None | Minimum measured = -6.448 None";"";"";"99.5"
"CHEMBL3740727";"";"None";"719.79";"2";"2.06";"ASAP-0000570";"N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1";"IC50";"'='";"1028.0";"nM";"5.99";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.108 None | IC50 CI (lower) = 0.988 uM | IC50 CI (upper) = 1.069 uM | Maximum measured = 99.67 None | Maximum response = 100.0 % | Minimum measured = 0.737 None | R squared = 0.999 None";"";"";"1.028"
"CHEMBL5604471";"";"None";"332.41";"0";"3.92";"ASAP-0029790";"Cc1c(C(=O)Nc2cc(-c3cccnc3)ccn2)cc(C2CC2)n1C";"IC50";"'='";"4832.0";"nM";"5.32";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.861 None | IC50 CI (lower) = 4.483 uM | IC50 CI (upper) = 5.209 uM | Maximum measured = 98.96 None | Maximum response = 100.0 % | Minimum measured = -3.028 None | R squared = 0.996 None";"";"";"4.832"
"CHEMBL5605549";"";"None";"294.31";"0";"1.71";"ASAP-0029783";"O=C(Nc1ccc2c(c1)CNC2)c1cccc2[nH]c(=O)[nH]c12";"IC50";"'='";"65525.0";"nM";"4.18";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.683 None | IC50 CI (lower) = 62.43 uM | IC50 CI (upper) = 68.77 uM | Maximum measured = 68.28 None | Maximum response = 100.0 % | Minimum measured = -0.988 None | R squared = 0.992 None";"";"";"65.525"
"CHEMBL5605462";"";"None";"491.94";"0";"4.17";"ASAP-0027759";"CNC(=O)[C@H](Nc1cc(Cl)cc(NC(=O)OCc2ccccc2)c1)c1cccc(-c2nn[nH]n2)c1";"IC50";"'='";"46518.0";"nM";"4.33";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.493 None | IC50 CI (lower) = 41.74 uM | IC50 CI (upper) = 51.85 uM | Maximum measured = 93.57 None | Maximum response = 100.0 % | Minimum measured = -7.783 None | R squared = 0.953 None";"";"";"46.518"
"CHEMBL3740727";"";"None";"719.79";"2";"2.06";"ASAP-0000570";"N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1";"IC50";"'='";"1000.0";"nM";"6.00";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.182 None | IC50 CI (lower) = 0.945 uM | IC50 CI (upper) = 1.059 uM | Maximum measured = 99.41 None | Maximum response = 100.0 % | Minimum measured = 1.783 None | R squared = 0.997 None";"";"";"1.0"
"CHEMBL3740727";"";"None";"719.79";"2";"2.06";"ASAP-0000570";"N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1";"IC50";"'='";"1695.0";"nM";"5.77";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.153 None | IC50 CI (lower) = 1.613 uM | IC50 CI (upper) = 1.781 uM | Maximum measured = 100.95 None | Maximum response = 100.0 % | Minimum measured = -1.231 None | R squared = 0.998 None";"";"";"1.695"
"CHEMBL5606160";"";"None";"372.40";"0";"4.22";"ASAP-0030089";"O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]c(-c3ccccc3)nc12";"IC50";"'='";"3672.0";"nM";"5.43";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.523 None | IC50 CI (lower) = 2.452 uM | IC50 CI (upper) = 5.499 uM | Maximum measured = 89.22 None | Maximum response = 100.0 % | Minimum measured = -6.225 None | R squared = 0.828 None";"";"";"3.672"
"CHEMBL5604703";"";"None";"326.79";"0";"3.38";"ASAP-0029875";"Cc1nc2c(C(=O)Nc3ccc4c(c3)CNC4)cc(Cl)cc2[nH]1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 0.544 None | Maximum measured = 30.39 None | Maximum response = 100.0 % | Minimum measured = -3.72 None | R squared = 0.159 None";"";"";"99.5"
"CHEMBL5598658";"";"None";"355.87";"0";"3.72";"ASAP-0029621";"CNC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = 0.894 None | Minimum measured = -23.45 None";"";"";"99.5"
"CHEMBL5598743";"";"None";"425.96";"0";"4.27";"ASAP-0029555";"O=C(NC1CCOCC1)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.11 None | Maximum measured = 12.16 None | Maximum response = 100.0 % | Minimum measured = -4.915 None | R squared = 0.597 None";"";"";"99.5"
"CHEMBL5598576";"";"None";"405.88";"0";"4.36";"ASAP-0029491";"O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.79 None | Maximum measured = 32.43 None | Maximum response = 100.0 % | Minimum measured = -4.103 None | R squared = 0.912 None";"";"";"99.5"
"CHEMBL5598746";"";"None";"435.96";"0";"4.02";"ASAP-0029471";"Cn1cc(CNC(=O)[C@H](Nc2ccc3c(c2)CNC3)c2cc(Cl)cc(C3CC3)c2)cn1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 11.41 None | Maximum measured = 7.18 None | Maximum response = 100.0 % | Minimum measured = -5.5 None | R squared = 0.319 None";"";"";"99.5"
"CHEMBL5598718";"";"None";"298.78";"0";"3.43";"ASAP-0029525";"Clc1cc(CNc2ccc3c(c2)CNC3)c2cn[nH]c2c1";"IC50";"'='";"30908.0";"nM";"4.51";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.356 None | IC50 CI (lower) = 28.4 uM | IC50 CI (upper) = 33.64 uM | Maximum measured = 85.14 None | Maximum response = 100.0 % | Minimum measured = -4.042 None | R squared = 0.983 None";"";"";"30.908"
"CHEMBL5598786";"";"None";"296.30";"0";"2.56";"ASAP-0029497";"O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]ncc12";"IC50";"'='";"68230.0";"nM";"4.17";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 0.968 None | IC50 CI (lower) = 60.58 uM | IC50 CI (upper) = 76.85 uM | Maximum measured = 55.66 None | Maximum response = 100.0 % | Minimum measured = -2.271 None | R squared = 0.98 None";"";"";"68.23"
"CHEMBL5598605";"";"None";"305.34";"0";"3.20";"ASAP-0029713";"O=C(Nc1ccc2c(c1)CNC2)c1cccc(-c2cnco2)c1";"IC50";"'='";"20321.0";"nM";"4.69";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.055 None | IC50 CI (lower) = 18.95 uM | IC50 CI (upper) = 21.79 uM | Maximum measured = 95.09 None | Maximum response = 100.0 % | Minimum measured = -3.904 None | R squared = 0.992 None";"";"";"20.321"
"CHEMBL5598765";"";"None";"420.90";"0";"3.59";"ASAP-0029650";"Cn1cc(CCc2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(Cl)cc3[nH]2)cn1";"IC50";"'='";"21587.0";"nM";"4.67";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.253 None | IC50 CI (lower) = 18.35 uM | IC50 CI (upper) = 25.4 uM | Maximum measured = 81.39 None | Maximum response = 100.0 % | Minimum measured = -4.32 None | R squared = 0.964 None";"";"";"21.587"
"CHEMBL5604470";"";"None";"397.41";"0";"4.10";"ASAP-0031299";"N#Cc1ccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)cc1";"IC50";"'='";"1680.0";"nM";"5.78";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.462 None | IC50 CI (lower) = 1.525 uM | IC50 CI (upper) = 1.85 uM | Maximum measured = 95.92 None | Maximum response = 100.0 % | Minimum measured = -4.1 None | R squared = 0.985 None";"";"";"1.68"
"CHEMBL5604338";"";"None";"360.46";"0";"3.49";"ASAP-0031404";"O=C(Nc1ccc2c(c1)CNC2)c1ccc2[nH]cc(C3CCNCC3)c2c1";"IC50";"'='";"31174.0";"nM";"4.51";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.859 None | IC50 CI (lower) = 29.64 uM | IC50 CI (upper) = 32.78 uM | Maximum measured = 95.9 None | Maximum response = 100.0 % | Minimum measured = -3.84 None | R squared = 0.992 None";"";"";"31.174"
"CHEMBL5604332";"";"None";"312.76";"0";"3.07";"ASAP-0027808";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12";"IC50";"'='";"69217.0";"nM";"4.16";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.291 None | IC50 CI (lower) = 65.83 uM | IC50 CI (upper) = 72.78 uM | Maximum measured = 63.58 None | Maximum response = 100.0 % | Minimum measured = -0.857 None | R squared = 0.994 None";"";"";"69.217"
"CHEMBL5598717";"";"None";"565.08";"2";"6.65";"ASAP-0027928";"O=C(Nc1cc(Cl)cc([C@H]2CN(Cc3ccccc3)C[C@@H]2c2cccc(-c3nn[nH]n3)c2)c1)OCc1ccccc1";"IC50";"'='";"6635.0";"nM";"5.18";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.202 None | IC50 CI (lower) = 6.226 uM | IC50 CI (upper) = 7.071 uM | Maximum measured = 98.36 None | Maximum response = 100.0 % | Minimum measured = -2.827 None | R squared = 0.996 None";"";"";"6.635"
"CHEMBL5605186";"";"None";"461.01";"1";"6.83";"ASAP-0027756";"O=C(Nc1cc(Cl)cc([C@H]2C[C@@H]2c2cccc(C3CCNCC3)c2)c1)OCc1ccccc1";"IC50";"'='";"6279.0";"nM";"5.20";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 4.195 None | IC50 CI (lower) = 5.297 uM | IC50 CI (upper) = 7.443 uM | Maximum measured = 99.64 None | Maximum response = 100.0 % | Minimum measured = -13.14 None | R squared = 0.981 None";"";"";"6.279"
"CHEMBL5605526";"";"None";"409.87";"0";"4.80";"ASAP-0016806";"NCc1cccc(NC(=O)c2cc(Cl)cc(NC(=O)OCc3ccccc3)c2)c1";"IC50";"'='";"51118.0";"nM";"4.29";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.313 None | IC50 CI (lower) = 47.19 uM | IC50 CI (upper) = 55.37 uM | Maximum measured = 85.83 None | Maximum response = 100.0 % | Minimum measured = -8.718 None | R squared = 0.97 None";"";"";"51.118"
"CHEMBL5605090";"";"None";"336.37";"0";"3.67";"ASAP-0030071";"C=CC[C@H]1NCc2cc(NC(=O)c3cc(F)cc4[nH]ncc34)ccc21";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 6.384 None | Maximum measured = 5.993 None | Maximum response = 100.0 % | Minimum measured = -1.936 None | R squared = 0.507 None";"";"";"99.5"
"CHEMBL5605716";"";"None";"305.34";"0";"2.80";"ASAP-0029967";"O=C(Nc1ccc2c(c1)CNC2)c1cccc2nc(O)ccc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 4.962 None | Maximum measured = 8.963 None | Maximum response = 100.0 % | Minimum measured = -4.15 None | R squared = 0.598 None";"";"";"99.5"
"CHEMBL5604164";"";"None";"345.32";"0";"4.04";"ASAP-0030028";"O=C(Nc1ccc2c(c1)CNC2)c1cccc2[nH]c(C(F)(F)F)cc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = 1.145 None | Minimum measured = -6.449 None";"";"";"99.5"
"CHEMBL5604667";"";"None";"422.49";"0";"4.20";"ASAP-0031355";"CC(C)c1nnc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)s1";"IC50";"'='";"21779.0";"nM";"4.66";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.043 None | IC50 CI (lower) = 15.77 uM | IC50 CI (upper) = 30.08 uM | Maximum measured = 68.13 None | Maximum response = 100.0 % | Minimum measured = -4.215 None | R squared = 0.882 None";"";"";"21.779"
"CHEMBL5605103";"";"None";"386.43";"0";"4.53";"ASAP-0031310";"Cc1ccccc1-c1nc2c(C(=O)Nc3ccc4c(c3)CNC4)cc(F)cc2[nH]1";"IC50";"'='";"2189.0";"nM";"5.66";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.425 None | IC50 CI (lower) = 1.859 uM | IC50 CI (upper) = 2.576 uM | Maximum measured = 96.27 None | Maximum response = 100.0 % | Minimum measured = -2.105 None | R squared = 0.96 None";"";"";"2.189"
"CHEMBL5604531";"";"None";"402.43";"0";"4.23";"ASAP-0031290";"COc1cccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)c1";"IC50";"'='";"5415.0";"nM";"5.27";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.493 None | IC50 CI (lower) = 4.071 uM | IC50 CI (upper) = 7.204 uM | Maximum measured = 87.21 None | Maximum response = 100.0 % | Minimum measured = -3.508 None | R squared = 0.922 None";"";"";"5.415"
"CHEMBL5604114";"";"None";"488.94";"0";"4.42";"ASAP-0027813";"O=C(Nc1cc(Cl)cc([C@H](C#CCO)Nc2cccc(-c3nn[nH]n3)c2)c1)OCc1ccccc1";"IC50";"'='";"12720.0";"nM";"4.90";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.053 None | IC50 CI (lower) = 11.51 uM | IC50 CI (upper) = 14.06 uM | Maximum measured = 98.22 None | Maximum response = 100.0 % | Minimum measured = -4.838 None | R squared = 0.98 None";"";"";"12.72"
"CHEMBL5606153";"";"None";"423.90";"1";"5.11";"ASAP-0021119";"Cc1ccc(NC(=O)c2cc(Cl)cc(NC(=O)OCc3ccccc3)c2)cc1CN";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.519 None | Maximum measured = 43.98 None | Maximum response = 100.0 % | Minimum measured = -17.96 None | R squared = 0.519 None";"";"";"99.5"
"CHEMBL5604414";"";"None";"464.91";"1";"5.53";"ASAP-0023480";"O=C(Nc1cc(Cl)cc(C(=O)Nc2cccc([C@H]3C[C@H]3C(=O)O)c2)c1)OCc1ccccc1";"IC50";"'='";"25164.0";"nM";"4.60";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.325 None | IC50 CI (lower) = 22.49 uM | IC50 CI (upper) = 28.15 uM | Maximum measured = 97.92 None | Maximum response = 100.0 % | Minimum measured = -7.23 None | R squared = 0.969 None";"";"";"25.164"
"CHEMBL5604328";"";"None";"459.90";"0";"4.95";"ASAP-0028861";"N#C[C@H](Nc1cccc(-c2nn[nH]n2)c1)c1cc(Cl)cc(NC(=O)OCc2ccccc2)c1";"IC50";"'='";"10024.0";"nM";"5.00";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.404 None | IC50 CI (lower) = 9.127 uM | IC50 CI (upper) = 11.01 uM | Maximum measured = 100.46 None | Maximum response = 100.0 % | Minimum measured = -5.169 None | R squared = 0.981 None";"";"";"10.024"
"CHEMBL5605251";"";"None";"493.41";"1";"5.97";"ASAP-0015849";"CC(C)CNC(=O)c1cc(Cl)ccc1NS(=O)(=O)c1ccc(Oc2ccccc2Cl)cc1";"IC50";"'='";"14372.0";"nM";"4.84";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.145 None | IC50 CI (lower) = 11.39 uM | IC50 CI (upper) = 18.13 uM | Maximum measured = 83.39 None | Maximum response = 100.0 % | Minimum measured = -11.24 None | R squared = 0.915 None";"";"";"14.372"
"CHEMBL5606457";"";"None";"464.87";"0";"3.61";"ASAP-0023274";"O=C(Nc1cc(Cl)cc(C(=O)Nc2cccc(-n3nn[nH]c3=O)c2)c1)OCc1ccccc1";"IC50";"'='";"11555.0";"nM";"4.94";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.673 None | IC50 CI (lower) = 10.43 uM | IC50 CI (upper) = 12.8 uM | Maximum measured = 98.52 None | Maximum response = 100.0 % | Minimum measured = -9.322 None | R squared = 0.976 None";"";"";"11.555"
"CHEMBL5604806";"";"None";"420.85";"1";"5.94";"ASAP-0027839";"O=C(Nc1cc(Cl)cc(-c2ccc3[nH]c(C(=O)O)cc3c2)c1)OCc1ccccc1";"IC50";"'='";"5819.0";"nM";"5.24";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.144 None | IC50 CI (lower) = 5.486 uM | IC50 CI (upper) = 6.173 uM | Maximum measured = 100.15 None | Maximum response = 100.0 % | Minimum measured = -2.475 None | R squared = 0.997 None";"";"";"5.819"
"CHEMBL5598860";"";"None";"325.41";"0";"3.36";"ASAP-0029521";"Cc1c(C(=O)Nc2cc([C@H]3CCOC3)ccn2)cc(C2CC2)n1C";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = -0.768 None | Minimum measured = -4.775 None";"";"";"99.5"
"CHEMBL5598575";"";"None";"399.92";"0";"3.74";"ASAP-0029415";"COCCNC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 11.43 None | Maximum measured = 8.614 None | Maximum response = 100.0 % | Minimum measured = -9.137 None | R squared = 0.23 None";"";"";"99.5"
"CHEMBL5606232";"";"None";"278.31";"0";"2.42";"ASAP-0030093";"O=C(Nc1ccc2c(c1)CNC2)c1cccc2cn[nH]c12";"IC50";"'='";"49934.0";"nM";"4.30";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.865 None | IC50 CI (lower) = 45.44 uM | IC50 CI (upper) = 54.87 uM | Maximum measured = 77.69 None | Maximum response = 100.0 % | Minimum measured = -1.829 None | R squared = 0.973 None";"";"";"49.934"
"CHEMBL5599838";"";"None";"459.98";"1";"5.16";"ASAP-0031456";"CC(C)NC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]c(-c3ccccc3)nc12";"IC50";"'='";"2056.0";"nM";"5.69";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 0.962 None | IC50 CI (lower) = 1.871 uM | IC50 CI (upper) = 2.26 uM | Maximum measured = 95.82 None | Maximum response = 100.0 % | Minimum measured = 2.067 None | R squared = 0.993 None";"";"";"2.056"
"CHEMBL5605097";"";"None";"386.43";"0";"4.53";"ASAP-0031293";"Cc1cccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)c1";"IC50";"'='";"5919.0";"nM";"5.23";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.984 None | IC50 CI (lower) = 4.471 uM | IC50 CI (upper) = 7.834 uM | Maximum measured = 79.56 None | Maximum response = 100.0 % | Minimum measured = -6.56 None | R squared = 0.9 None";"";"";"5.919"
"CHEMBL5605639";"";"None";"341.72";"0";"3.61";"ASAP-0029970";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C(F)(F)F)n1";"IC50";"'='";"7254.0";"nM";"5.14";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.941 None | IC50 CI (lower) = 6.578 uM | IC50 CI (upper) = 8.0 uM | Maximum measured = 101.69 None | Maximum response = 100.0 % | Minimum measured = -1.395 None | R squared = 0.99 None";"";"";"7.254"
"CHEMBL5604695";"";"None";"352.83";"0";"4.19";"ASAP-0029944";"C=CC[C@H]1NCc2cc(NC(=O)c3cc(Cl)cc4[nH]ncc34)ccc21";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = -0.655 None | Minimum measured = -9.834 None";"";"";"99.5"
"CHEMBL5605910";"";"None";"413.91";"0";"3.13";"ASAP-0029914";"CCOCCNC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 10.66 None | Maximum measured = 8.006 None | Maximum response = 100.0 % | Minimum measured = -4.75 None | R squared = 0.327 None";"";"";"99.5"
"CHEMBL5604180";"";"None";"312.76";"0";"3.07";"ASAP-0029911";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2cn[nH]c12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 4.008 None | Maximum measured = 47.56 None | Maximum response = 100.0 % | Minimum measured = -4.349 None | R squared = 0.955 None";"";"";"99.5"
"CHEMBL5598685";"";"None";"323.83";"0";"4.50";"ASAP-0029597";"N#C[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = 0.166 None | Minimum measured = -62.3 None";"";"";"99.5"
"CHEMBL3740727";"";"None";"719.79";"2";"2.06";"ASAP-0000570";"N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1";"IC50";"'='";"865.0";"nM";"6.06";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.101 None | IC50 CI (lower) = 0.844 uM | IC50 CI (upper) = 0.887 uM | Maximum measured = 100.24 None | Maximum response = 100.0 % | Minimum measured = 3.126 None | R squared = 0.999 None";"";"";"0.865"
"CHEMBL5605184";"";"None";"311.32";"0";"2.18";"ASAP-0030065";"O=C1Cc2c(cc(F)cc2C(=O)Nc2ccc3c(c2)CNC3)N1";"IC50";"'='";"36199.0";"nM";"4.44";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.855 None | IC50 CI (lower) = 32.78 uM | IC50 CI (upper) = 39.98 uM | Maximum measured = 95.85 None | Maximum response = 100.0 % | Minimum measured = -1.825 None | R squared = 0.979 None";"";"";"36.199"
"CHEMBL5604989";"";"None";"390.39";"0";"4.36";"ASAP-0031443";"O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]c(-c3cccc(F)c3)nc12";"IC50";"'='";"2687.0";"nM";"5.57";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.977 None | IC50 CI (lower) = 2.304 uM | IC50 CI (upper) = 3.134 uM | Maximum measured = 96.09 None | Maximum response = 100.0 % | Minimum measured = -3.624 None | R squared = 0.971 None";"";"";"2.687"
"CHEMBL5598597";"";"None";"326.79";"0";"3.41";"ASAP-0029027";"CN1Cc2ccc(NC(=O)c3cc(Cl)cc4[nH]ncc34)cc2C1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 0.97 None | Maximum measured = 38.76 None | Maximum response = 100.0 % | Minimum measured = -2.416 None | R squared = 0.975 None";"";"";"99.5"
"CHEMBL5605115";"";"None";"375.20";"0";"3.32";"ASAP-0030792";"O=C(Nc1cc(Br)c2c(c1)CNC2)c1cc(F)cc2[nH]ncc12";"IC50";"'='";"75519.0";"nM";"4.12";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.812 None | IC50 CI (lower) = 69.96 uM | IC50 CI (upper) = 81.52 uM | Maximum measured = 64.44 None | Maximum response = 100.0 % | Minimum measured = -0.799 None | R squared = 0.975 None";"";"";"75.519"
"CHEMBL5605521";"";"None";"296.35";"0";"3.17";"ASAP-0030106";"O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2c1CCC2";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = 1.851 None | Minimum measured = -31.23 None";"";"";"99.5"
"CHEMBL5598610";"";"None";"383.88";"0";"3.50";"ASAP-0029974";"CC(C)NC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12";"IC50";"'='";"34366.0";"nM";"4.46";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.172 None | IC50 CI (lower) = 30.97 uM | IC50 CI (upper) = 38.14 uM | Maximum measured = 81.12 None | Maximum response = 100.0 % | Minimum measured = -4.919 None | R squared = 0.984 None";"";"";"34.366"
"CHEMBL5606384";"";"None";"411.90";"0";"2.76";"ASAP-0028903";"CNC(=O)[C@H](Nc1cc(CN)cc(-c2nn[nH]n2)c1)c1cc(Cl)cc(C2CC2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.052 None | Maximum measured = 7.423 None | Maximum response = 100.0 % | Minimum measured = -3.012 None | R squared = 0.431 None";"";"";"99.5"
"CHEMBL5598898";"";"None";"323.78";"0";"3.74";"ASAP-0029711";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2ccncc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.956 None | Maximum measured = 36.63 None | Maximum response = 100.0 % | Minimum measured = -4.697 None | R squared = 0.931 None";"";"";"99.5"
"CHEMBL5598611";"";"None";"326.79";"0";"3.08";"ASAP-0029588";"Cn1cc2cc(Cl)cc(C(=O)Nc3ccc4c(c3)CNC4)c2n1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = -1.893 None | Minimum measured = -35.85 None";"";"";"99.5"
"CHEMBL5606266";"";"None";"277.33";"0";"3.02";"ASAP-0029756";"O=C(Nc1ccc2c(c1)CNC2)c1ccc2[nH]ccc2c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.101 None | Maximum measured = 13.18 None | Maximum response = 100.0 % | Minimum measured = -4.706 None | R squared = 0.489 None";"";"";"99.5"
"CHEMBL5605022";"";"None";"321.32";"0";"2.43";"ASAP-0031265";"N#Cc1cc2c(cc1NC(=O)c1cc(F)cc3[nH]ncc13)CNC2";"IC50";"'='";"59669.0";"nM";"4.22";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 0.991 None | IC50 CI (lower) = 50.9 uM | IC50 CI (upper) = 69.95 uM | Maximum measured = 62.07 None | Maximum response = 100.0 % | Minimum measured = -4.29 None | R squared = 0.964 None";"";"";"59.669"
"CHEMBL5605673";"";"None";"425.90";"0";"4.15";"ASAP-0027729";"CCc1cc(C(=O)Nc2cccc(-n3nn[nH]c3=O)c2)sc1-c1ccc(Cl)cc1";"IC50";"'='";"11401.0";"nM";"4.94";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.819 None | IC50 CI (lower) = 10.17 uM | IC50 CI (upper) = 12.78 uM | Maximum measured = 95.1 None | Maximum response = 100.0 % | Minimum measured = -6.589 None | R squared = 0.975 None";"";"";"11.401"
"CHEMBL5605183";"";"None";"389.38";"0";"2.84";"ASAP-0030767";"O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]ncc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 0.805 None | Maximum measured = 21.46 None | Maximum response = 100.0 % | Minimum measured = -2.539 None | R squared = 0.899 None";"";"";"99.5"
"CHEMBL5598576";"";"None";"405.88";"0";"4.36";"ASAP-0030775";"O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = -0.12 None | Minimum measured = -17.46 None";"";"";"99.5"
"CHEMBL5605532";"";"None";"341.46";"1";"5.10";"ASAP-0016252";"c1cc(C2CCN(Cc3c[nH]c4ccccc34)CC2)c2ccncc2c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = -7.196 None | Minimum measured = -11.83 None";"";"";"99.5"
"CHEMBL3740727";"";"None";"719.79";"2";"2.06";"ASAP-0000570";"N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1";"IC50";"'='";"920.0";"nM";"6.04";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.074 None | IC50 CI (lower) = 0.9 uM | IC50 CI (upper) = 0.941 uM | Maximum measured = 99.41 None | Maximum response = 100.0 % | Minimum measured = 3.834 None | R squared = 0.999 None";"";"";"0.92"
"CHEMBL5606202";"";"None";"344.46";"0";"4.73";"ASAP-0021052";"Cc1[nH]c2ccccc2c1CN1CCC(c2c[nH]c3ncccc23)CC1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = -5.485 None | Minimum measured = -12.35 None";"";"";"99.5"
"CHEMBL5606033";"";"None";"293.33";"0";"2.04";"ASAP-0029950";"O=C1Cc2cc(C(=O)Nc3ccc4c(c3)CNC4)ccc2N1";"IC50";"'='";"5256.0";"nM";"5.28";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.546 None | IC50 CI (lower) = 4.751 uM | IC50 CI (upper) = 5.814 uM | Maximum measured = 99.75 None | Maximum response = 100.0 % | Minimum measured = -3.951 None | R squared = 0.992 None";"";"";"5.256"
"CHEMBL5605499";"";"None";"387.24";"0";"2.48";"ASAP-0029933";"Cn1c(=O)[nH]c2c(C(=O)Nc3ccc4c(c3)CNC4)cc(Br)cc21";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = 1.285 None | Minimum measured = -182.12 None";"";"";"99.5"
"CHEMBL5598684";"";"None";"433.31";"0";"4.85";"ASAP-0029352";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Br)cc2[nH]c(-c3ccccc3)nc12";"IC50";"'='";"1242.0";"nM";"5.91";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.442 None | IC50 CI (lower) = 1.076 uM | IC50 CI (upper) = 1.434 uM | Maximum measured = 97.84 None | Maximum response = 100.0 % | Minimum measured = -6.263 None | R squared = 0.961 None";"";"";"1.242"
"CHEMBL5604118";"";"None";"367.47";"0";"3.55";"ASAP-0031158";"NCCc1csc2cc(C(=O)Nc3cc([C@H]4CCOC4)ccn3)ccc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = 1.002 None | Minimum measured = -7.285 None";"";"";"99.5"
"CHEMBL5605908";"";"None";"403.42";"0";"3.63";"ASAP-0031141";"COc1cc(-c2cc(NC(=O)c3cc(F)cc4[nH]ncc34)cc3c2CNC3)ccn1";"IC50";"'='";"82838.0";"nM";"4.08";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604072";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 1 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 1 (strain Nauru/West Pac/1974) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 1";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAAEISWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTGGGGSGGGGSGVLWDTPSPPEVERAVLDDGIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGAVLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNTGEEVQVIAVEPGKNPKNVQTAPGTFKTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPLPEIEDEVFRK";"";"";"CHEMBL5705862";"NS3 protease";"dengue virus type 1";"SINGLE PROTEIN";"CHEMBL5604064";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.519 None | IC50 CI (lower) = 69.87 uM | IC50 CI (upper) = 98.22 uM | Maximum measured = 56.19 None | Maximum response = 100.0 % | Minimum measured = -7.635 None | R squared = 0.924 None";"";"";"82.838"
